Bioequivalence Study of 20 mg Omeprazole Capsules in Indonesia Healthy Subject

NACompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 10, 2020

Primary Completion Date

January 14, 2021

Study Completion Date

February 3, 2021

Conditions
Drug Use
Interventions
DRUG

Omeprazole 20 mg Capsules

Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production

Trial Locations (1)

10520

PT Pharma Metric Labs, Jakarta Pusat

All Listed Sponsors
collaborator

PT Pharma Metric Labs

INDUSTRY

lead

PT Kalbe Farma Tbk

INDUSTRY

NCT05849883 - Bioequivalence Study of 20 mg Omeprazole Capsules in Indonesia Healthy Subject | Biotech Hunter | Biotech Hunter